MEIRAGTX HLDGSDL-,0000388

MeiraGTx significantly beat analyst expectations in Q2 2026: EPS $1.71 vs. consensus loss of $0.31, revenue $321.4 million and net income of $160.7 million. The revenue jump resulted from contract manufacturing and transaction revenues with Lilly and from recognizing previously deferred collaboration revenues with Janssen and Hologen. Strategic progress includes an FDA Breakthrough Therapy designation for AAV2-hAQP1, the acquisition of rights to bota-vec from Johnson & Johnson, and an agreement with Oberland Capital for up to $400 million in investments. Cash and cash equivalents rose to $145.4 million, and management is targeting global regulatory filings for bota-vec in 2026 and a potential BLA filing for AAV2-hAQP1 by mid-2027. » Więcej na de.investing.com

MeiraGTx shares rose to a 52-week high of about $13.71–$13.72 and delivered a total return of roughly 85% over the past year. InvestingPro currently rates the stock as overvalued, while three analysts raised their earnings estimates and the company remains unprofitable. MeiraGTx announced a strategic collaboration with Hologen to develop a delivery device for gene therapies and elected three Class II directors through 2029. Several banks raised price targets, including Piper Sandler ($30), RBC Capital ($24) and H.C. Wainwright ($20). » Więcej na de.investing.com

MeiraGTx and Hologen have signed strategic license and collaboration agreements for the research, development, manufacturing and commercialization of gene therapies for Parkinson’s disease and genetic forms of obesity, as well as a delivery device for the CNS. Hologen committed to an upfront payment of $200 million, of which $105 million has already been paid; Hologen will hold 70% of the shares in Hologen Neuro AI Limited and MeiraGTx 30%. Hologen also acquired a minority stake in MeiraGTx Manufacturing with an option to increase its holding to up to 40%, and MeiraGTx retains a buyback option. MeiraGTx additionally planned an equity raise of $100 million at $9 per share to fund operations through the second half of 2028 and repurchased the gene therapy bota-vec from Johnson & Johnson ( $25 million upfront). Analysts raised price targets and maintained positive ratings given clinical data and the strategic moves. » Więcej na de.investing.com